DDInter833 DDInter205
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bictegravir
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Calcium acetate
Calcium acetate {u} may lead to a major life threatening interaction when taken with {v} Bictegravir
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Glycerol phenylbutyrate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Calcium acetate (Compound) and Calcium acetate may lead to a major life threatening interaction when taken with Bictegravir